Search for Inclusive b → sl^+l^-

We have searched for the effective flavor changing neutral-current decays b→sl^+l^- using an inclusive method. We set upper limits on the branching ratios B(b→se^+e^-)<5.7×10^(-5), B(b→sμ^+μ^-)<5.8×10^(-5), and B(b→se^±μ^∓)<2.2×10^(-5) [at 90% confidence level (C.L.)]. Combing the dielectron and dimuon decay modes we find B(b→sl^+l^-)<4.2×10^(-5) (at 90% C.L.)

Search for the X(1812) in B±→K±ωϕB^{\pm} \to K^{\pm} \omega \phi

We report on a search for the X(1812) state in the decay $B^{\pm} \to K^{\pm} \omega \phi$ with a data sample of $657\times10^6$ $B\bar{B}$ pairs collected with the Belle detector at the KEKB $e^+e^-$ collider. No significant signal is observed. An upper limit ${\cal B}(B^{\pm} \to K^{\pm} X(1812),X(1812) \to \omega \phi)<3.2\times 10^{-7}$ (90% C.L.) is determined. We also constrain the three-body decay branching fraction to be ${\cal B}(B^{\pm} \to K^{\pm} \omega \phi)$ $<$ 1.9 $\times 10^{-6}$ (90% C.L.).Comment: 5pages,2 figures(3 figure files). submitted to PRD(RC

A Study of Exclusive Charmless Semileptonic B Decays and Extraction of |V_{ub}| at CLEO

We have studied semileptonic B decay to the exclusive charmless states pi, rho/omega, eta and eta' using the full 15.5 fb^-1 CLEO Upsilon(4S) sample, with measurements performed in subregions of phase space to minimize dependence on a priori knowledge of the form factors involved. We find total branching fractions B(B^0 -> pi^-l^+nu) = (1.37 +- 0.15_stat +- 0.11_sys) x 10^-4 and B(B^0 -> rho^- l^+ nu) = (2.93 +- 0.37_stat +- 0.37_sys) x 10^-4. We find evidence for B^+ -> eta' l^+ nu, with B(B^+ -> eta' l^+ nu) = (2.66 +- 0.80_stat +- 0.56_sys) x 10^-4 and 1.20 x 10^-4 eta' l^+ nu) < 4.46 x 10^-4 (90% CL). We also limit B(B^+ -> eta l^+ nu) < 1.01 x 10^-4 (90% CL). By combining our B -> pi l nu information with unquenched lattice calculations, we find |V_ub| = (3.6 +- 0.4 +- 0.2 +0.6 -0.4) x 10^-3, where the errors are statistical, experimental systematic, and theoretical systematic, respectively.Comment: 35 pages, 15 figures; revise

Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset

&lt;p&gt;&lt;b&gt;Background and Purpose:&lt;/b&gt; Desmoteplase is a novel plasminogen activator with favorable features in vitro compared with available agents. This study evaluated safety and efficacy of intravenous (IV) desmoteplase in patients with perfusion/diffusion mismatch on MRI 3 to 9 hours after onset of acute ischemic stroke.&lt;/p&gt; &lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; DEDAS was a placebo-controlled, double-blind, randomized, dose-escalation study investigating doses of 90 μg/kg and 125 μg/kg desmoteplase. Eligibility criteria included baseline National Institute of Health Stroke Scale (NIHSS) scores of 4 to 20 and MRI evidence of perfusion/diffusion mismatch. The safety end point was the rate of symptomatic intracranial hemorrhage. Primary efficacy co-end points were MRI reperfusion 4 to 8 hours after treatment and good clinical outcome at 90 days. The primary analyses were intent-to-treat. Before unblinding, a target population, excluding patients violating specific MRI criteria, was defined.&lt;/p&gt; &lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; Thirty-seven patients were randomized and received treatment (intent-to-treat; placebo: n=8; 90 μg/kg: n=14; 125 μg/kg: n=15). No symptomatic intracranial hemorrhage occurred. Reperfusion was achieved in 37.5% (95% CI [8.5; 75.5]) of placebo patients, 18.2% (2.3; 51.8) of patients treated with 90 μg/kg desmoteplase, and 53.3% (26.6; 78.7) of patients treated with 125 μg/kg desmoteplase. Good clinical outcome at 90 days occurred in 25.0% (3.2; 65.1) treated with placebo, 28.6% (8.4; 58.1) treated with 90 μg/kg desmoteplase and 60.0% (32.3; 83.7) treated with 125 μg/kg desmoteplase. In the target population (n=25), the difference compared with placebo increased and was statistically significant for good clinical outcome with 125 μg/kg desmoteplase (P=0.022).&lt;/p&gt; &lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; Treatment with IV desmoteplase 3 to 9 hours after ischemic stroke onset appears safe. At a dose of 125 μg/kg desmoteplase appeared to improve clinical outcome, especially in patients fulfilling all MRI criteria. The results of DEDAS generally support the results of its predecessor study, Desmoteplase in Acute Ischemic Stroke (DIAS).&lt;/p&gt

Measurement of B0→π+π−π+π−B^0\to\pi^+\pi^-\pi^+\pi^- Decays and Search for B0→ρ0ρ0B^0\to\rho^0\rho^0

We report on a search for the decay $B^0\to\rho^0\rho^0$ and other charmless modes with a $\pi^+\pi^-\pi^+\pi^-$ final state, including $B^0\to\rho^0\pi^+\pi^-$, non-resonant $B^0\to 4\pi^{\pm}$, $B^0\to\rho^0f_0(980)$, $B^0\to f_0(980)f_0(980)$ and $B^0\to f_0(980)\pi^+\pi^-$. These results are obtained from a data sample containing 657 million $B \overline B$ pairs collected with the Belle detector at the KEKB asymmetric-energy $e^+e^-$ collider. We set an upper limit on $\mathcal{B}(B^0\to\rho^0\rho^0)$ of $1.0\times 10^{-6}$ at the 90% confidence level (C.L.). From our $B^0\to\rho^0\rho^0$ measurement and an isospin analysis, we determine the Cabibbo-Kobayashi-Maskawa phase $\phi_2$ to be $91.7 \pm 14.9$ degrees. We find excesses in $B^0\to \rho^0\pi^+\pi^-$ and non-resonant $B^0\to 4\pi^{\pm}$ with 1.3$\sigma$ and 2.5$\sigma$ significance, respectively. The corresponding branching fractions are less than $12.0 \times 10^{-6}$ and $19.3 \times 10^{-6}$ at the 90% C.L. In addition, we set 90% C.L. upper limits as follows: $\mathcal{B}(B^0\to\rho^0f_0(980))< 0.3 \times 10^{-6}$, $\mathcal{B}(B^0\to f_0(980)f_0(980))< 0.1 \times 10^{-6}$, and $\mathcal{B}(B^0\to f_0(980)\pi^+\pi^-)< 3.8 \times 10^{-6}$.Comment: 6 pages, 2 figures. Submitted to PRD(RC

Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial

&lt;p&gt;&lt;b&gt;Background and Purpose:&lt;/b&gt; NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from ischemic stroke. We conducted analyses on additional end points and sensitivity analyses to confirm our findings.&lt;/p&gt; &lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; We randomized 1722 patients with acute ischemic stroke to a 72-hour infusion of placebo or intravenous NXY-059 within 6 hours of stroke onset. The primary outcome was disability at 90 days, as measured by the modified Rankin Scale (mRS), a 6-point scale ranging from 0 (no residual symptoms) to 5 (bed-bound, requiring constant care). Additional and exploratory analyses included mRS at 7 and 30 days; subgroup interactions with final mRS; assessments of activities of daily living by Barthel index; and National Institutes of Health Stroke Scale (NIHSS) neurological scores at 7 and 90 days.&lt;/p&gt; &lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; NXY-059 significantly improved the distribution of the mRS disability score compared with placebo at 7, 30, and 90 days (Cochran-Mantel-Haenszel test P=0.002, 0.004, 0.038, respectively; 90-day common odds ratio 1.20; 95% CI, 1.01 to 1.42). The benefit was not attributable to any specific baseline characteristic, stratification variable or subgroup interaction. Neurological scores were improved at 7 days (odds ratio [OR], 1.46; 95% CI, 1.13, 1.89; P=0.003) and the Barthel index was improved at 7 and 30 days (OR, 1.55; 95% CI, 1.22, 1.98; P&#60;0.0001; OR, 1.27; 95% CI, 1.01, 1.59; P=0.02).&lt;/p&gt; &lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; NXY-059 within 6 hours of acute ischemic stroke significantly reduced disability. Benefit on neurological scores and activities of daily living was detectable early but not significant at 90 days; however, our trial was underpowered to measure effects on the neurological examination. The benefit on disability is not confounded by interactions and is supported by other outcome measures.&lt;/p&gt

The Contribution of Bc Mesons to the Search for B->tau nu Decays at LEP

We study the contribution of B_c mesons to the search for B->tau nu decays. We find that at LEP the contributions from B_u and B_c mesons can be comparable. This observation can have a relevant impact on the extraction of constraints on new physics (such as charged-Higgs contributions) from current LEP limits on B->tau nu final states. Inclusion of the B_c contribution can reduce the current L3 limit on Tan(beta)/M_H from 0.38/GeV (90%CL) down to 0.27/GeV (90%CL).Comment: 8 pages, Latex, epsfig, 1 figur